The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.
about
HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrationsMolecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, RwandaRev-RRE Functional Activity Differs Substantially Among Primary HIV-1 Isolates.The role of recombination in the emergence of a complex and dynamic HIV epidemic.HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics?The evolution of HIV-1 group M genetic variability in Southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutationsContribution of immunological and virological factors to extremely severe primary HIV type 1 infection.Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North AfricaHIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in CameroonRecombinant viruses initiated the early HIV-1 epidemic in Burkina Faso.Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina.Mechanisms and factors that influence high frequency retroviral recombinationMolecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in ItalyThe Use of Bioinformatics for Studying HIV Evolutionary and Epidemiological History in South America.HIV-infected sex workers with beneficial HLA-variants are potential hubs for selection of HIV-1 recombinants that may affect disease progressionDeciphering How HIV-1 Intersubtype Recombination Shapes Viral Fitness and Disease Progression.In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.Near full-length HIV type 1M genomic sequences from Cameroon : Evidence of early diverging under-sampled lineages in the countryHuman immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted virusesThe challenge of HIV-1 subtype diversity.Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions.HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries.Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China.Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionalityQuantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolutionSubtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.Genetic diversity in HIV-1 subtype C LTR from Brazil and Mozambique generates new transcription factor-binding sites.Trends of subtype variation of human immunodeficiency virus type 1 in Zhejiang Province, China.HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3.Inference of global HIV-1 sequence patterns and preliminary feature analysis.Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.Cognitive function among antiretroviral treatment-naïve individuals infected with HIV-1 Subtype G versus CRF02_AG in Nigeria.Divergent HIV-1 strains (CRF92_C2U and CRF93_cpx) co-circulating in the Democratic Republic of the Congo: Phylogenetic insights on the early evolutionary history of subtype C.Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter CohortsHIV-1 nonsubtype B distribution across certain resource-rich countries
P2860
Q27355483-97D52D8A-A9E1-4480-BB12-CBC6D740B71DQ28482242-E3B56D60-856F-4BE4-BA32-C08F4D5E88FDQ30276860-198B4396-7565-4190-87AD-CDC81FBF7DD0Q30387214-1A7E84CB-03CD-4688-87E4-E7B2FD3CA3CAQ30388624-D1294CB8-EAAB-42CC-BEAD-CFB094334C2FQ33570778-530B5C41-FEBA-41CF-A24E-6664085998F1Q33589386-040FB5EB-BF43-4A06-8176-C8D0B1B4FB1BQ33897090-DABD4B0E-D0B7-4D2F-A71A-70173BA69502Q34243456-731D165C-FB6F-4F67-BAE4-113189C45697Q34737547-9446EC57-AF82-4764-9EDE-146EA0790780Q35054197-F9DE7C07-4B6A-42BC-A3B9-A88248A43337Q35125087-E5936E85-D24C-435C-8AEF-72236B4CE698Q35146589-8243DA8B-E012-44C6-920F-87B612DAF746Q35276750-D6870854-83C8-44B5-87FF-E4335AFB64FDQ35508265-7F91E30B-17B9-4092-8BFA-ADC877C9F231Q35579280-FE31FE51-F301-4300-9375-8FA319FC03B8Q35749934-6007DC33-1F2F-4BEC-9511-485D04D2F6AEQ35795079-B4F368CA-6806-4021-8D61-458F48F4538CQ36099861-3BCBDF86-E884-4141-AB85-9F324E667039Q36144358-EC3CDE71-4E6A-49E4-BC4C-072A666D2819Q36744775-D0219D15-CCA8-46AE-BCFD-AA0329504286Q36974671-585D2FD0-3E07-42C3-B6B4-35994C35AFA7Q37038453-9BFB4453-11D3-4383-B9F7-BD09B078BD6BQ37139889-13CF665E-44C6-4D36-B538-20858753DE13Q37186690-BD709B54-E2FA-4AA0-B173-C02F7128277CQ37220020-1ADFE691-7FEB-4B80-89AE-362D8C9EC57FQ37305864-4E1E7CCE-BD31-4FDF-B57E-26BA5AFD8809Q37452459-8CB2FDB1-569C-4B2E-8EDD-C2448DC6A557Q38706845-FED405FF-AB91-4F61-9CC1-E7EC1BFA743BQ39471859-A6D25A4B-CACE-4E46-9539-226C60B1D033Q41463492-7A880A94-2613-45F8-ADA5-1F3C37AFA234Q41655911-D277551F-43F2-49E2-A772-1AD820B571C0Q41918917-B7F65D53-9C8A-4855-A6CD-24440EA84E30Q42277493-BBEF4B88-5EAB-425E-8FAC-F010732158CFQ42279217-DA92E98E-0F82-4578-A22D-6424DFE47CE6Q42362648-88EAA88E-C606-47DD-95E7-928705B9576BQ46399734-5D4C9CBF-A154-4561-BDFB-49AFC982C508Q46832256-CA645A93-D331-48D4-8061-EB5799A506ABQ57708705-6DBEEB7E-A5A6-4903-A522-B89A8A5D3FB3Q58485636-9EAB638E-5F11-48F4-91AB-30667F64716E
P2860
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The predominance of Human Immu ...... ed to its replicative fitness.
@ast
The predominance of Human Immu ...... ed to its replicative fitness.
@en
The predominance of Human Immunodeficiency Virus type 1
@nl
type
label
The predominance of Human Immu ...... ed to its replicative fitness.
@ast
The predominance of Human Immu ...... ed to its replicative fitness.
@en
The predominance of Human Immunodeficiency Virus type 1
@nl
prefLabel
The predominance of Human Immu ...... ed to its replicative fitness.
@ast
The predominance of Human Immu ...... ed to its replicative fitness.
@en
The predominance of Human Immunodeficiency Virus type 1
@nl
P2093
P2860
P356
P1433
P1476
The predominance of Human Immu ...... ed to its replicative fitness.
@en
P2093
Christelle Butel
Claude Clybergh
Eitel Mpoudi-Ngolle
Guido Vanham
Harr F Njai
Kevin K Ariën
Nicole Vidal
Youssef Gali
P2860
P2888
P356
10.1186/1742-4690-3-40
P577
2006-07-03T00:00:00Z
P5875
P6179
1005041241